The receptor tyrosine kinase ALK has a pivotal function in various malignant diseases, and its exceptional behavior is documented by the fact that chromosomal ALK rearrangements have been described in completely different malignancies, namely inflammatory myofibroblastic tumors, anaplastic large-cell lymphomas and lung cancer of the NSCLC subtype. [1] [2] [3] Recently, the expression of a particular ALK fusion protein, namely TPM4-ALK, in esophageal squamous cell carcinoma was suggested. 4 ALK belongs to the insulin-receptor superfamily, and its expression is normally restricted to specific regions of the central nervous system. Chromosomal translocations fusing and activating the ALK locus foster tumor genesis by its constitutive tyrosine kinase activity. In cells with ALK fusion proteins, a number of overlapping and interconnected signaling pathways are subsequently activated, for example RAS-ERK, JAK-STAT and PI3K-AKT. Enhanced proliferation and survival through inhibition of apoptosis are key features of this ALK-mediated activation of signaling cascades. 5 An involvement of ALK in myeloid malignancies, however, has not yet been reported.
Here, we show that ALK is rarely but recurrently rearranged in children with myeloid diseases, indicating the great clinical potential that anti-ALK therapies may acquire in the near future.
Among 1708 successfully analyzed karyotypes of children with myeloproliferative diseases (1278 AML, 430 MDS), provided by classical cytogenetics, six were found to have an abnormality involving the chromosomal band 2p23 (Table 1;  Supplementary Table 1) . Two children showed a t(2;4)(p23;q27) (pt. 1) and a del(2)(p23) (pt. 2) as a part of a complex karyotype. In three of the remaining four (pts. [3] [4] [5] , an inv(2)(p23q13) was detected, whereas patient 6 had a t(2;2)(p23;q11B13).
Interestingly, in three of the latter (pts. 3, 4, 6), a monosomy 7 (À7) was found in addition.
To confirm the breakpoint in 2p23, FISH analysis was performed using the LSI ALK Dual Color Break Apart Rearrangement Probe on bone marrow cells of all six patients. A splitting of the green and red signal was found in patients 3, 4 and 6 ( Figure 1) , whereas in the remaining three patients, two fusion signals appeared, indicating no involvement of the ALK gene. By the use of chromosome arm-specific painting probes, translocation t(2;2) in pt. 6 was also proved (Figure 1 ).
Of special interest were the cytogenetic findings of pt. 4, who had two aberrant clones, one with the inv(2)(p23q13) only and another clone with the additional loss of chromosome 7. To prove that the À7 abnormality occurred secondary to the ALK splitting, we performed co-hybridization of the ALK probe together with a chromosome 7 centromere probe (Supplementary Figure 1 ). Whereas almost no cells with À7 as sole abnormality were found (far below the cutoff of 6%), we counted 25% of cells with an ALK splitting only but two normal centromere signals for chromosome 7. In all, 42% of the cells had both aberrations, an ALK rearrangement and a À7. The remaining cells revealed a wild-type configuration at both loci. Thus, we conclude that the ALK rearrangement preceded the monosomy 7 in this case. In contrast, at subsequent relapse, the same patient showed ALK splitting in conjunction with the À7 in all malignant cells. This finding was confirmed by G-banding showing the karyotype 45,XY,inv(2)(p23q13),À7 [8] /46,XY [3] at this time point.
On the basis of an earlier report in which a translocation t(2;2)(p23;q13) resulted in a RAN-binding protein 2 (RanBP2)-ALK fusion mRNA, 1 we performed an RT-PCR analysis for the presence of such a chimeric mRNA. This analysis showed a distinct band of 240 bp for patients 3, 4, and 6, whereas pts. 1 and 2 were negative (Supplementary Figure 2) . Unfortunately, there was no material left from pt. 5 for this analysis. Subsequent sequencing of the PCR products revealed the identical breakpoints described previously in all cases ( Figure 2 ). To investigate whether ALK fusion genes might cause in myeloproliferative diseases, we first performed quantitative real-time PCR for the tyrosine kinase domain of ALK. We revealed an easily detectible ALK-expression in patients 3, 4 and 6 and patient 4 at his relapse (Figure 2 ), whereas in a control group of 10 patients without ALK-rearrangement, a remarkable expression of the ALK-gene was not found (data not shown).
An elevated level of phosphorylation due to ectopic ALK protein has been shown to activate several cellular signaling pathways including the JAK/STAT cascade. As a consequence, ALK expression should render hematopoietic cells hypersensitive to cytokines that use this mode of signal transduction. For myeloid cells, this is predominantly GM-CSF. Therefore, in a second step, we determined whether also myeloid cells derived from the patients described in this report showed pronounced responses to this cytokine. Vital cells were available from patients 4 and 6 and patient 4 at relapse. Bone marrow cells of these patients could be cultivated in GM-CSF concentrations ranging from 10 to 0.001 ng GM-CSF/ml, whereas PBMCs did not show any proliferation under these conditions (Figure 2 ). To exclude that GM-CSF hypersensitivity was caused by other well-known activators of the RAS signaling pathway in JMML, we sequenced PTPN11, k-RAS, n-RAS and the GAP-domain of NF1. All sequences revealed to be wild type (data not shown).
To further study the effect of ectopic ALK expression on cytokine-induced proliferation, primary bone marrow cells were retrovirally transduced with full-length ALK or empty viruses as control. Development toward the myeloid lineage was induced in methocel cultures containing limiting amounts of IL-3, IL-6 and SCF, with an additional supplement of varying concentrations of GM-CSF. Compared with controls, ALK-expressing cells showed a greatly enhanced colony forming potential and a reduced dependency on cytokines indicative of increased sensitivity toward JAK/STAT signals in general (Figure 2) .
Clinical data of the three positive patients are summarized in Table 1 . Initial diagnosis was difficult in all three cases and was finally defined as MDS or JMML, AML M4 and JMML, respectively. On the basis of the fact of identical genetic aberrations and at least major concordant clinical data, all three patients have to be embraced to the same disorder, which might be an atypical JMML-like myeloid disorder or AML.
In this study, we provide three children with an ambiguous myeloid disorder and RanBP2/ALK rearrangement recruited by an additional monosomy 7. In at least one of our patients latter was shown to be the secondary aberration. The finding that ALK fusion transcripts can also be found in healthy blood donors 6 suggests that additional cooperating genetic events may be required for a full malignant phenotype.
However, in this study, we could show myeloid forming potential of gene fusions leading to an appreciable expression of tyrosine kinase domain of ALK. Of note, a recent massspectrometry approach identified PTPN11 as a substrate of NPM/ALK. (c) G-banded chromosomes 2 and FISH analysis of patient 6 using the VYSIS LSI ALK Dual Color, Break Apart Probe and chromosome arm specific (CAP) for 2p (green) and 2q (red) probes, respectively. In interphases, one fusion and a red and a green signal were found; metaphases showed that the 3 0 ALK signal (red) was translocated on the q-arm of the other chromosome 2 and CAP probes also confirm the translocation t(2;2). (d) Schematic demonstration of the t(2;2)(p23;q11B13). growth in ALK-positive lymphoma cells. Thus, it seems reasonable to speculate that activation of ALK in myeloid progenitors have similar effects on PTPN11 leading to GM-CSF hypersensitivity.
Several small molecules aiming to suppress ALK-mediated transformation have been described (for review see 8 ) . When a suitable ALK inhibitor may become clinically available, patients with myeloproliferative disease in whom ALK aberrations have been documented may also benefit from those targeted therapies.
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